vs

Side-by-side financial comparison of AVITA Medical, Inc. (RCEL) and Spire Global, Inc. (SPIR). Click either name above to swap in a different company.

AVITA Medical, Inc. is the larger business by last-quarter revenue ($17.6M vs $15.8M, roughly 1.1× Spire Global, Inc.). AVITA Medical, Inc. runs the higher net margin — -66.0% vs -176.6%, a 110.7% gap on every dollar of revenue. On growth, AVITA Medical, Inc. posted the faster year-over-year revenue change (-4.3% vs -26.9%). AVITA Medical, Inc. produced more free cash flow last quarter ($-6.1M vs $-16.2M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs -32.6%).

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

Spire Global, Inc. is a space-to-cloud data and analytics company that specializes in the tracking of global data sets powered by a large constellation of nanosatellites, such as the tracking of maritime, aviation and weather patterns.

RCEL vs SPIR — Head-to-Head

Bigger by revenue
RCEL
RCEL
1.1× larger
RCEL
$17.6M
$15.8M
SPIR
Growing faster (revenue YoY)
RCEL
RCEL
+22.6% gap
RCEL
-4.3%
-26.9%
SPIR
Higher net margin
RCEL
RCEL
110.7% more per $
RCEL
-66.0%
-176.6%
SPIR
More free cash flow
RCEL
RCEL
$10.0M more FCF
RCEL
$-6.1M
$-16.2M
SPIR
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
-32.6%
SPIR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RCEL
RCEL
SPIR
SPIR
Revenue
$17.6M
$15.8M
Net Profit
$-11.6M
$-28.0M
Gross Margin
81.2%
40.2%
Operating Margin
-59.1%
-164.1%
Net Margin
-66.0%
-176.6%
Revenue YoY
-4.3%
-26.9%
Net Profit YoY
-0.3%
42.7%
EPS (diluted)
$-0.37
$-0.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RCEL
RCEL
SPIR
SPIR
Q4 25
$17.6M
$15.8M
Q3 25
$17.1M
$12.7M
Q2 25
$18.4M
$19.2M
Q1 25
$18.5M
$23.9M
Q4 24
$18.4M
$21.7M
Q3 24
$19.5M
$28.6M
Q2 24
$15.2M
$25.4M
Q1 24
$11.1M
$34.8M
Net Profit
RCEL
RCEL
SPIR
SPIR
Q4 25
$-11.6M
$-28.0M
Q3 25
$-13.2M
$-19.7M
Q2 25
$-9.9M
$119.6M
Q1 25
$-13.9M
$-20.7M
Q4 24
$-11.6M
$-48.8M
Q3 24
$-16.2M
$-12.5M
Q2 24
$-15.4M
$-16.6M
Q1 24
$-18.7M
$-25.5M
Gross Margin
RCEL
RCEL
SPIR
SPIR
Q4 25
81.2%
40.2%
Q3 25
81.3%
36.6%
Q2 25
81.2%
48.9%
Q1 25
84.7%
36.8%
Q4 24
87.6%
32.4%
Q3 24
83.7%
44.5%
Q2 24
86.1%
43.0%
Q1 24
86.4%
26.5%
Operating Margin
RCEL
RCEL
SPIR
SPIR
Q4 25
-59.1%
-164.1%
Q3 25
-53.6%
-166.1%
Q2 25
-60.5%
-122.7%
Q1 25
-63.9%
-106.5%
Q4 24
-54.1%
-144.1%
Q3 24
-70.6%
-48.0%
Q2 24
-102.8%
-48.6%
Q1 24
-155.0%
-34.4%
Net Margin
RCEL
RCEL
SPIR
SPIR
Q4 25
-66.0%
-176.6%
Q3 25
-77.3%
-155.3%
Q2 25
-53.9%
623.4%
Q1 25
-74.9%
-86.5%
Q4 24
-63.0%
-225.2%
Q3 24
-82.9%
-43.7%
Q2 24
-101.3%
-65.2%
Q1 24
-168.0%
-73.3%
EPS (diluted)
RCEL
RCEL
SPIR
SPIR
Q4 25
$-0.37
$-0.85
Q3 25
$-0.46
$-0.61
Q2 25
$-0.38
$3.72
Q1 25
$-0.53
$-0.77
Q4 24
$-0.44
$-1.93
Q3 24
$-0.62
$-0.50
Q2 24
$-0.60
$-0.68
Q1 24
$-0.73
$-1.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RCEL
RCEL
SPIR
SPIR
Cash + ST InvestmentsLiquidity on hand
$18.2M
$81.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-16.6M
$112.9M
Total Assets
$56.4M
$211.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RCEL
RCEL
SPIR
SPIR
Q4 25
$18.2M
$81.8M
Q3 25
$23.3M
$96.8M
Q2 25
$15.7M
$117.6M
Q1 25
$25.8M
$35.9M
Q4 24
$35.9M
$19.2M
Q3 24
$44.4M
$36.6M
Q2 24
$54.1M
$45.8M
Q1 24
$68.2M
$63.7M
Total Debt
RCEL
RCEL
SPIR
SPIR
Q4 25
Q3 25
Q2 25
Q1 25
$103.7M
Q4 24
$103.1M
Q3 24
$4.9M
Q2 24
$4.9M
Q1 24
$123.1M
Stockholders' Equity
RCEL
RCEL
SPIR
SPIR
Q4 25
$-16.6M
$112.9M
Q3 25
$-6.7M
$133.1M
Q2 25
$-12.9M
$149.2M
Q1 25
$-4.6M
$3.7M
Q4 24
$4.5M
$-11.7M
Q3 24
$12.2M
$30.8M
Q2 24
$23.9M
$40.3M
Q1 24
$32.6M
$52.5M
Total Assets
RCEL
RCEL
SPIR
SPIR
Q4 25
$56.4M
$211.0M
Q3 25
$63.7M
$224.3M
Q2 25
$58.1M
$239.5M
Q1 25
$69.6M
$208.8M
Q4 24
$79.7M
$193.6M
Q3 24
$81.1M
$224.2M
Q2 24
$87.8M
$230.8M
Q1 24
$97.4M
$252.3M
Debt / Equity
RCEL
RCEL
SPIR
SPIR
Q4 25
Q3 25
Q2 25
Q1 25
27.92×
Q4 24
Q3 24
0.16×
Q2 24
0.12×
Q1 24
2.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RCEL
RCEL
SPIR
SPIR
Operating Cash FlowLast quarter
$-5.4M
$-4.3M
Free Cash FlowOCF − Capex
$-6.1M
$-16.2M
FCF MarginFCF / Revenue
-34.7%
-102.1%
Capex IntensityCapex / Revenue
3.8%
75.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-33.5M
$-92.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RCEL
RCEL
SPIR
SPIR
Q4 25
$-5.4M
$-4.3M
Q3 25
$-5.2M
$-12.0M
Q2 25
$-10.2M
$-35.1M
Q1 25
$-10.3M
$-8.4M
Q4 24
$-8.1M
$-19.2M
Q3 24
$-7.2M
$14.0M
Q2 24
$-12.8M
$-4.4M
Q1 24
$-20.9M
$-8.8M
Free Cash Flow
RCEL
RCEL
SPIR
SPIR
Q4 25
$-6.1M
$-16.2M
Q3 25
$-6.2M
$-20.4M
Q2 25
$-10.8M
$-38.7M
Q1 25
$-10.5M
$-17.3M
Q4 24
$-9.7M
$-24.3M
Q3 24
$-11.0M
$5.1M
Q2 24
$-15.4M
$-9.9M
Q1 24
$-22.0M
$-15.9M
FCF Margin
RCEL
RCEL
SPIR
SPIR
Q4 25
-34.7%
-102.1%
Q3 25
-36.1%
-161.3%
Q2 25
-58.4%
-201.7%
Q1 25
-56.9%
-72.6%
Q4 24
-52.7%
-112.2%
Q3 24
-56.1%
17.8%
Q2 24
-101.6%
-39.0%
Q1 24
-198.2%
-45.7%
Capex Intensity
RCEL
RCEL
SPIR
SPIR
Q4 25
3.8%
75.1%
Q3 25
5.5%
66.2%
Q2 25
2.8%
18.8%
Q1 25
1.2%
37.3%
Q4 24
8.8%
23.5%
Q3 24
19.2%
31.2%
Q2 24
17.5%
21.8%
Q1 24
10.3%
20.3%
Cash Conversion
RCEL
RCEL
SPIR
SPIR
Q4 25
Q3 25
Q2 25
-0.29×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons